Benchmark immunostainer

Manufactured by Roche

Sourced in United States, Switzerland

The Benchmark immunostainer is a laboratory instrument designed for automated immunohistochemistry and in situ hybridization procedures. It is capable of performing staining protocols on tissue samples.

Automatically generated - may contain errors

Lab products found in correlation

Anti cleaved caspase 3 asp175, by Santa Cruz Biotechnology (1 mentions) Ventana dp 200, by Roche (1 mentions)

Close spelling variants of this product

Benchmark automated immunostainer Ventana BenchMark ULTRA Immunostainer Ventana Benchmark automated immunostainer Ventana Benchmark Immunostainer BenchMark ULTRA automated immunostainer Benchmark XT immunostainer BenchMark ULTRA Immunostainer Ventana Benchmark XT Immunostainer

8 protocols using benchmark immunostainer

Breast Cancer Subtyping via Immunohistochemistry

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunostaining was done for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 count using a Ventana Benchmark immunostainer using the manufacturer's supplied antibodies. Positive status for ER and PR was defined as having nuclear staining in at least 10% of invasive tumors cells. HER2 was scored based on a 0 to 3 scale according to the criteria set by ASCO (American Society of Clinical Oncology). In the final analysis, a score of 3+ was considered overexpressed or positive and a score ≤2 as negative. Fluorescence in situ hybridization for HER2 amplification was not performed.
Breast cancer subtypes were defined according to the IHC expression of ER/PR/HER2 and Ki-67 count as follows: luminal A (ER+/PR+, HER2-, Ki‐67 ≤ 14%), luminal B (ER+/PR+, HER2+ or ER+/PR+, HER2-, Ki‐67 > 14%), HER2 enriched (ER-, PR-, HER2+), and triple negative (ER-, PR-, HER2-).

Darre T., Tchaou M., Djiwa T., Simgban P., Amavi A.K., N'Timon B., Amadou A., Bombonne M., Sama B., Amégbor K, & Napo-Koura G. (2020). Male Breast Cancer in Togo: Imaging and Clinicopathological Findings. International Journal of Breast Cancer, 2020, 3056067.

+ Open protocol

+ Expand

Breast Cancer Subtyping by Immunohistochemistry

Check if the same lab product or an alternative is used in the 5 most similar protocols

The study material consisted of biopsies and operating pieces fixed in 10% buffered formalin and came from various health structures in the country.
Immunostaining was done for Estrogen Receptor (ER) Progesterone Receptor (PR), Human Epidermal growth factor Receptor2 (HER2) and Ki-67 count using a Ventana Benchmark immunostainer using the manufacturers supplied antibodies. ER and PR positive nuclei greater than 1% were considered hormone receptor positive. HER2 was scored based on a 0 to 3 scale according to the criteria set by ASCO (American Society of Clinical Oncology) [11 (link)]. In the final analysis, a score of 3+ was considered overexpressed or positive and a score ≤ 2 as negative. Fluorescence in situ hybridization for HER2 amplification was not performed.
Breast cancer subtypes were defined according to the IHC expression of ER/PR/HER2 and Ki-67 count as follow:

Luminal A (ER + / PR +, HER2 -, Ki - 67 \leq 14 % or grade 1 or 2 tumor grading),

Luminal B (ER + / PR +, HER2 + or ER + / PR +, HER2 -, Ki - 67 > 14 % or grade3),

HER2 enriched (ER -, PR -, HER2 +),

Triple negative (ER -, PR -, HER2 -) .

Adani-Ifè A., Amégbor K., Doh K, & Darré T. (2020). Breast cancer in togolese women: immunohistochemistry subtypes. BMC Women's Health, 20, 261.

+ Open protocol

+ Expand

Quantification of Angiogenesis and Apoptosis

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Briefly, tumor tissue samples from all the different treatment groups were fixed in 10% neutral-buffered formalin for 24 h and embedded in paraffin for histology and IHC. Sections (5-μM-thick) were incubated with anti-PECAM-1 antibody (M-20) (1:200, #sc1506, Santa Cruz Biotechnology) and anti-cleaved Caspase-3 (Asp175) (1:300, #sc7272, Santa Cruz Biotechnology) at 4 °C overnight. Negative controls were carried out by omitting the primary antibodies. Immunostaining was accomplished using a Benchmark immunostainer (Ventana, Tuscon, AZ). Immunoreaction was displayed using the avidin–biotin–peroxidase complex (ABC) method. Peroxidase activity was visualized with diaminobenzidine. Counterstaining was performed with haematoxylin. Quantification of caspase 3 positive cells and CD31 was performed as previously described [21 (link),27 (link)].

Di Desidero T., Antonelli A., Orlandi P., Ferrari S.M., Fioravanti A., Alì G., Fontanini G., Basolo F., Francia G, & Bocci G. (2017). Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer. Cancer letters, 411, 35-43.

+ Open protocol

+ Expand

Comprehensive Immunohistochemical Profiling of Tumor Tissue

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC was performed as previously described [25 (link)]. Briefly, tumour tissue samples were fixed in 10 % neutral-buffered formalin for 12–24 h and embedded in paraffin. Sections of the tumour (5 μm thick) were stained with haematoxylin and eosin. Immunostaining was carried out with a Benchmark immunostainer (Ventana, Tucson, AZ, USA) and using the avidin–biotin-peroxidase complex (ABC) method and counterstained with haematoxylin. Negative controls were performed by omitting the primary antibodies. IHC was evaluated independently by two pathologists (G.A. and G.Fo.). Sections stained with haematoxylineosin were evaluated for the mitotic index (MI) by counting mitotic figures under a microscope. The microvessel number was established using anti-CD31 polyclonal antibody (clone JC70; cat. 760–4378, Ventana Medical System). Ki-67 staining was done using the rabbit monoclonal primary antibody (clone 30–9; cat. 790–1286; Ventana Medical System). Ki-67 staining was measured as the percentage of cancer cells with positively stained nuclei. The identification of apoptosis was performed using a rabbit polyclonal antibody that recognizes active caspase-3 (diluted 1:2000; cat. ab2302, Abcam, Cambridge, UK). The apoptotic index was determined as a percentage of the apoptotic cells out of the total number of the examined cells.

Di Desidero T., Orlandi P., Gentile D., Banchi M., Alì G., Kusmic C., Armanetti P., Cayme G.J., Menichetti L., Fontanini G., Francia G, & Bocci G. (2020). Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer. Pharmacological research, 158, 104920.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Thyroid Carcinomas

Check if the same lab product or an alternative is used in the 5 most similar protocols

Thyroid samples were from “Ospedale del Mare” (ASL NA 1 Centro, Naples, Italy). Thyroid carcinomas were classified according to the America Joint Committee on Cancer (AJCC) TNM system. All patients agreed to make their tumor tissue available for research studies. This study was approved by the Internal Reviewing Board. Normal and tumor thyroid specimens were fixed in 10% neutral buffered formalin, embedded in paraffin, and 4 μm sections were stained with hematoxylin–eosin according to standard procedures.
MDM2 expression and RSK phosphorylation were detected by incubating the slides, respectively, with the mouse monoclonal antibody anti-MDM2 (clone IF2) #337100 (Invitrogen) and the mouse monoclonal antibody phospho-RSK2 sc-374664 (SantaCruz Biotechnology).
Immunoreactions were displayed by the avidin–biotin–peroxidase complex (ABC) method (Ultraview Universal DAB Detect kit Ventana, Roche, Basel, Switzerland) by a Benchmark Immunostainer (Ventana, Tucson, AZ, USA). Negative controls were carried out by omitting the primary antibodies.
The sections were observed under a light microscope and photographed using a digital scanner (Ventana DP 200, Roche) at 40× magnification.

Maietta I., Del Peschio F., Buonocore P., Viscusi E., Laudati S., Iannaci G., Minopoli M., Motti M.L, & De Falco V. (2022). p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors. Cancers, 15(1), 121.

+ Open protocol

+ Expand

Breast Cancer Subtyping by IHC

Check if the same lab product or an alternative is used in the 5 most similar protocols

The study material consisted of biopsies and operating pieces xed in 10% buffered formalin and came from various health structures in the country.
Immunostaining was done for Estrogen Receptor (ER) Progesterone Receptor (PR), Human Epidermal growth factor Receptor2 (HER2) and Ki-67 count using a Ventana Benchmark immunostainer using the manufacturers supplied antibodies. ER and PR positive nuclei greater than 1% were considered hormone receptor positive. HER2 was scored based on a 0 to 3 scale according to the criteria set by ASCO (American Society of Clinical Oncology) [11] (link). In the nal analysis, a score of 3+ was considered overexpressed or positive and a score ≤ 2 as negative. Fluorescence in situ hybridization for HER2 ampli cation was not performed.
Breast cancer subtypes were de ned according to the IHC expression of ER/PR/HER2 and Ki-67 count as follow:
Luminal A (ER+/PR+, HER2-, Ki-67≤ 14% or grade 1 or 2 tumor grading), Luminal B (ER+/PR+, HER2+ or ER+/PR+, HER2-, Ki-67> 14% or grade3), HER2 enriched (ER-, PR-, HER2+), Triple negative (ER-, PR-, HER2-).

ADANI-IFE A., AMEGBOR K., DOH K., & DARRE T. (2020). Breast Cancer in Togolese Women: Immunohistochemistry Subtypes.

+ Open protocol

+ Expand

Breast Cancer Immunohistochemistry Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The study material consisted of biopsies and operating pieces xed in 10% buffered formalin and came from various health structures in the country.
Immunostaining was done for Estrogen Receptor (ER) Progesterone Receptor (PR), Human Epidermal growth factor Receptor2 (HER2) and Ki-67 count using a Ventana Benchmark immunostainer using the manufacturers supplied antibodies. Positive status for ER and PR was de ned as having nuclear staining in at least 10% of invasive tumors cells. HER2 was scored based on a 0 to 3 scale according to the criteria set by ASCO (American Society of Clinical Oncology) [11] . In the nal analysis, score of 3 + were considered overexpressed or positive and score ≤ 2 as negative. Fluorescence in situ hybridization for HER2 ampli cation was not performed.
Breast cancer subtypes were de ned according to the IHC expression of ER/PR and HER2 as follow:
Luminal A (ER + and/or PR+, HER2-), Luminal B (ER + and/or PR+, HER2+), HER2 enriched (ER-, PR-, HER2+), Triple negative (ER-, PR-, HER2-).

ADANI-IFE A., AMEGBOR K., DOH K., & DARRE T. (2020). Breast Cancer In Togolese Women: Immunohistochemistry Subtypes.

+ Open protocol

+ Expand

Breast Cancer Immunohistochemistry Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The study material consisted of biopsies and operating pieces xed in 10% buffered formalin and came from various health structures in the country.
Immunostaining was done for Estrogen Receptor (ER) Progesterone Receptor (PR), Human Epidermal growth factor Receptor2 (HER2) and Ki-67 count using a Ventana Benchmark immunostainer using the manufacturers supplied antibodies. Positive status for ER and PR was de ned as having nuclear staining in at least 10% of invasive tumors cells. HER2 was scored based on a 0 to 3 scale according to the criteria set by ASCO (American Society of Clinical Oncology) [11] . In the nal analysis, score of 3 + were considered overexpressed or positive and score ≤ 2 as negative. Fluorescence in situ hybridization for HER2 ampli cation was not performed.
Breast cancer subtypes were de ned according to the IHC expression of ER/PR and HER2 as follow:
Luminal A (ER + and/or PR+, HER2-), Luminal B (ER + and/or PR+, HER2+), HER2 enriched (ER-, PR-, HER2+), Triple negative (ER-, PR-, HER2-).

ADANI-IFE A., AMEGBOR K., DOH K., & DARRE T. (2020). Breast Cancer in Togolese Women: Immunohistochemistry Subtypes.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!